Liver & Organ Effects
Liver fat reduction, MASLD/NASH reversal, cardiovascular safety, and kidney function
Organs Beyond Fat
Retatrutide's glucagon component makes it uniquely suited for liver disease. A dedicated sub-study measured liver fat by MRI-PDFF and found reductions averaging over 80% at the highest dose -- potentially the most powerful MASLD therapy ever tested. This unit covers the liver data, cardiovascular monitoring results, and emerging signals in kidney function.
Liver Fat Reduction
MRI-PDFF data showing dramatic liver fat clearance across dose tiers.
MASLD & NASH
Implications for metabolic-associated steatotic liver disease and steatohepatitis.
Cardiovascular Effects
Heart rate, blood pressure, and cardiovascular safety monitoring data.
Kidney Function
Renal biomarkers and potential nephroprotective signals.